From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma

Bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) share three stubborn clinical problems: carcinoma in situ (CIS) is hard to find, residual lesions after transurethral resection of bladder tumor (TURBT) are easy to miss, and patients who do not respond to bacillus Calmette–Guérin (BCG) have few effective bladder-sparing options. The bladder and ureter are natural lumens that endoscopy can reach, which gives us an anatomical foothold for combining molecular detection, intraoperative navigation, and local therapy. This review follows how organic luminescent materials have moved from photodynamic diagnosis (PDD) to photoimmunotherapy (PIT), and looks at where clinical translation currently stands and what still blocks it. PDD improves CIS detection—several clinical studies support this—but false positives and the poor tissue penetration of blue light keep its use narrow. In the first-in-human trial of a Nectin-4-targeted fluorescent probe, biopsy diagnostic accuracy reached 96.0%, a sign that molecular imaging-guided surgery has entered clinical validation. On the therapeutic side, antibody–photoabsorber conjugates can selectively kill membrane-marker-positive tumor cells, and when paired with immune checkpoint inhibitors, they show promise in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). Insufficient tissue penetration, limited target specificity, and the absence of standardized light dosimetry remain the core barriers to translation. NIR-II imaging and activatable theranostic agents are likely to be the most important future directions.

Authors

Institutions

Publication Details

Journal
Molecules
Published
2026-11-19
DOI
https://doi.org/10.3390/molecules31224195
Primary Topic
Photodynamic Therapy Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma

杨占坡, Sheng Zeng, Minze Wang, Jinke Guo et al.
Molecules
Photodynamic Therapy Research Studies
article

From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma

杨占坡, Sheng Zeng, Minze Wang, Jinke Guo, Shilong Xue, Pengyu Chen, Qian Liu
article en

Abstract

Bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) share three stubborn clinical problems: carcinoma in situ (CIS) is hard to find, residual lesions after transurethral resection of bladder tumor (TURBT) are easy to miss, and patients who do not respond to bacillus Calmette–Guérin (BCG) have few effective bladder-sparing options. The bladder and ureter are natural lumens that endoscopy can reach, which gives us an anatomical foothold for combining molecular detection, intraoperative navigation, and local therapy. This review follows how organic luminescent materials have moved from photodynamic diagnosis (PDD) to photoimmunotherapy (PIT), and looks at where clinical translation currently stands and what still blocks it. PDD improves CIS detection—several clinical studies support this—but false positives and the poor tissue penetration of blue light keep its use narrow. In the first-in-human trial of a Nectin-4-targeted fluorescent probe, biopsy diagnostic accuracy reached 96.0%, a sign that molecular imaging-guided surgery has entered clinical validation. On the therapeutic side, antibody–photoabsorber conjugates can selectively kill membrane-marker-positive tumor cells, and when paired with immune checkpoint inhibitors, they show promise in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). Insufficient tissue penetration, limited target specificity, and the absence of standardized light dosimetry remain the core barriers to translation. NIR-II imaging and activatable theranostic agents are likely to be the most important future directions.

MoleculesVol. 31(22)
Tianjin First Center Hospital (CN), Tianjin Medical University (CN)
Photodynamic Therapy Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon